Research Analysts’ Weekly Ratings Changes for Qiagen (QGEN)

Several brokerages have updated their recommendations and price targets on shares of Qiagen (NYSE: QGEN) in the last few weeks:

• 5/7/2026 – Qiagen had its “hold” rating reaffirmed by TD Cowen. They now have a $40.00 price target on the stock, down from $46.00.
• 4/30/2026 – Qiagen had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $43.00 price target on the stock.
• 4/29/2026 – Qiagen was given a new $38.00 price target by Barclays PLC. They now have an “equal weight” rating on the stock.
• 4/29/2026 – Qiagen was given a new $43.00 price target by Robert W. Baird. They now have an “outperform” rating on the stock.
• 4/29/2026 – Qiagen was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/29/2026 – Qiagen was upgraded by Robert W. Baird from “hold” to “strong-buy”. They now have a $43.00 price target on the stock.
• 4/29/2026 – Qiagen had its price target lowered by JPMorgan Chase & Co. from $60.00 to $45.00. They now have an “overweight” rating on the stock.
• 4/29/2026 – Qiagen had its price target lowered by Citigroup Inc. from $55.00 to $38.00. They now have a “neutral” rating on the stock.
• 4/14/2026 – Qiagen was given a new $44.00 price target by Barclays PLC. They now have an “equal weight” rating on the stock.
• 4/14/2026 – Qiagen was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $44.00 price target on the stock.
• 3/28/2026 – Qiagen was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/27/2026 – Qiagen had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 3/13/2026 – Qiagen was upgraded by Deutsche Bank Aktiengesellschaft from “hold” to “buy”. They now have a $54.00 price target on the stock.

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.